How should an inguinal bubo be evaluated and treated?

Evaluation and Management of Inguinal Bubo

An inguinal bubo requires immediate fine-needle aspiration (FNA) for diagnostic confirmation, with empiric doxycycline 100 mg orally twice daily for 21 days initiated while awaiting results if sexually transmitted infection is suspected. 1, 2

Initial Clinical Assessment

Key Physical Examination Findings

• Document bubo characteristics systematically: size (measure diameter), consistency (firm vs. fluctuant), mobility vs. fixation to surrounding structures, tenderness, and presence of overlying skin changes 1, 3
• Assess for the "sign of groove" (depression between inguinal and femoral lymph node groups), which suggests lymphogranuloma venereum (LGV) but can also occur with non-Hodgkin's lymphoma 4
• Examine for primary lesions: inspect genitalia, perineum, perianal region, and lower extremities for ulcers, masses, or skin lesions that may represent the primary source 1, 3
• Determine laterality and associated findings: bilateral involvement suggests systemic disease or LGV, while unilateral presentation may indicate localized infection or metastatic disease 1, 3

Critical History Elements

• Sexual history within 30-60 days raises concern for sexually transmitted infections, particularly LGV or chancroid 2
• Note that 58% of patients with sexually transmitted inguinal buboes have no history of genital ulceration, so absence of ulcer history does not exclude STI 5
• Assess for systemic symptoms: fever, weight loss, night sweats (B symptoms suggest lymphoma or tuberculosis) 3, 6
• Document HIV risk factors and obtain HIV testing, as HIV-positive patients have higher rates of LGV and atypical presentations 7, 2

Diagnostic Algorithm

Immediate Diagnostic Steps

For all inguinal buboes, perform FNA as the initial diagnostic procedure with sensitivity of 91.7% and specificity of 98.2% for malignancy 1, 3

Laboratory Testing

• Send FNA specimen for:

  • Bacterial culture (Haemophilus ducreyi for chancroid) 5
  • Chlamydia trachomatis PCR (for LGV) 7, 5
  • Cytology and immunohistochemistry (to exclude lymphoma or metastatic disease) 4
  • Mycobacterial culture and PCR if tuberculosis is suspected 6

• Obtain serum testing:

  • HIV testing (mandatory at initial presentation) 2
  • Syphilis serology 5
  • Chlamydia trachomatis microimmunofluorescent antibody titer (≥256 suggests LGV) 7, 8

Imaging Strategy

• Ultrasound with high-frequency probe (>10 MHz) is first-line imaging to characterize the bubo and guide FNA 1
• CT abdomen and pelvis with IV contrast is indicated for:
  • Nodes ≥4 cm to assess extent and relationship to surrounding structures 3
  • Concern for deeper pelvic or retroperitoneal involvement 1, 3
  • Suspected metastatic disease from penile, anal, or gynecologic malignancy 3

Treatment Based on Etiology

Sexually Transmitted Infections (Most Common)

Lymphogranuloma Venereum (LGV)

• Doxycycline 100 mg orally twice daily for 21 days is first-line treatment 2, 3
• Alternative for pregnant/lactating women: Erythromycin base 500 mg orally four times daily for 21 days 2
• Treat sexual partners from the preceding 60 days 2

Chancroid

• Indicated when large, fluctuant, edematous buboes contain pus on aspiration 5
• Treatment regimens per CDC guidelines (specific regimen not detailed in provided evidence but should follow current CDC STI treatment guidelines)

Procedural Management of Fluctuant Buboes

• Needle aspiration is preferred over incision and drainage for fluctuant buboes to minimize scarring and complications 9
• Repeat aspiration may be necessary if fluid reaccumulates 9
• If bubo contains no pus on initial aspiration, inject 1 mL saline and reaspirate to improve diagnostic yield for Chlamydia trachomatis 5

Tuberculosis

• Standard four-drug antituberculous therapy for isolated tuberculous lymphadenitis, which is not uncommon in developing nations 6

Malignancy

If FNA is positive for malignancy:

• Immediate oncologic management based on primary tumor type 3
• For penile cancer: immediate inguinal lymph node dissection (ILND), with consideration of neoadjuvant chemotherapy for nodes ≥4 cm 3
• For lymphoma: refer to hematology-oncology for staging and systemic therapy 4

If FNA is negative but clinical suspicion remains high:

• Excisional biopsy for definitive diagnosis 3
• Surveillance every 3 months with re-biopsy if nodes enlarge or new symptoms develop 3

Critical Pitfalls to Avoid

• Do not assume all inguinal buboes are hernias: up to 50% of palpable inguinal nodes represent inflammatory changes, but 20-25% of clinically node-negative patients harbor occult metastases 1
• Do not rely on tenderness to exclude malignancy: tenderness does not exclude malignant etiology 3
• Do not overlook non-Hodgkin's lymphoma: the "sign of groove" is not specific for LGV and can occur with NHL 4
• Do not assume absence of genital ulcer excludes STI: 58% of patients with STI-related buboes have no history of genital ulceration 5
• Always perform bilateral examination even when bubo appears unilateral, due to crossover lymphatic drainage 1

Follow-Up Protocol

• Reassess at 3-7 days to evaluate response to antibiotic therapy 2
• HIV testing at 3-month follow-up for patients with genital ulcers or inguinal lymphadenopathy 2
• Biopsy is mandatory for fixed or matted nodes, or failure to respond to appropriate antibiotics within 7 days 2
• Continue clinical follow-up until complete resolution of signs and symptoms 2